Where does ISAC (immune-stimulating antibody conjugates) go from here?

Area of Science:

• Oncology
• Immunotherapy
• Drug Development

Background:

• Immune-stimulating antibody conjugates (ISACs) are designed like antibody-drug conjugates (ADCs) but use immune activators instead of cytotoxic drugs.
• ISACs aim to enhance immune responses for improved tumor targeting and elimination.
• Recent clinical trials since 2021 have highlighted significant challenges in ISAC development.

Purpose of the Study:

• To review the current status and challenges of immune-stimulating antibody conjugates (ISACs) as potential cancer therapeutics.
• To explore strategies for overcoming limitations in ISAC efficacy and safety.
• To assess the future potential of ISACs in oncology, particularly in combination therapies and for "cold" tumors.

Main Methods:

• Analysis of clinical trial data and scientific literature concerning ISACs.
• Review of strategies for optimizing ISAC design, including payload selection (TLR7 vs STING agonists), linker stability, and delivery methods.
• Evaluation of ISACs' potential for synergistic effects with existing immunotherapies.

Main Results:

• Clinical trials have identified key challenges including limited efficacy, systemic toxicity (e.g., cytokine release syndrome), and anti-drug antibody generation.
• Optimization strategies are being explored, focusing on payload choice, linker technology, and localized delivery approaches.
• Despite setbacks, ISACs demonstrate potential for treating "cold" tumors and enhancing current immunotherapies.

Conclusions:

• ISACs face substantial translational barriers, but their unique mechanism offers therapeutic promise in oncology.
• Further refinement of ISAC design parameters is crucial for clinical success.
• ISACs may ultimately become a transformative therapeutic modality, especially when combined with other cancer treatments.